Shin Kobayashi, Goro Honda, Masanao Kurata, Yukihiro Okuda, Katsunori Sakamoto, Katsuyuki Karasawa, Tachen Chang, Naoto Egawa, Terumi Kamisawa, Yasushi Omuro, Koji Tsuruta
BACKGROUND/AIMS: To determine the recommended dose (RD) for full-dose S-1 and low-dose gemcitabine combined with radiotherapy in patients with non-metastatic advanced pancreatic cancer. METHODOLOGY: Adult patients with non-metastatic advanced pancreatic cancer (Union for International Cancer Control T stage 3 or 4) were eligible. The weekly intravenous gemcitabine (level 0-1: 200 mg/ml,level 2: 300 mg/m on Days 1, 8, 15, 22, 29, 36) dose was escalated starting from level 1 in a 3+3 design along with full dose twice-daily oral S-1 (level 0: 60 mg/m2/day, level 1-2: 80 mg/ml/day), and was administered on the same days as radiotherapy (1...
June 2015: Hepato-gastroenterology